CDTX - Cidara Therapeutics posts new analyses from multiple rezafungin studies at ECCMID

Cidara Therapeutics (CDTX) posts new analyses from multiple studies of rezafungin, the company's treatment for candidemia at the 31st European Congress of Clinical Microbiology and Infectious Diseases ((ECCMID)).Rezafungin is Cidara’s novel, once-weekly echinocandin, under investigation in Phase 3 development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections.Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care, the company said."We look forward to corroborating the results of our Phase 2 STRIVE program in our ongoing Phase 3 RESTORE trial in which we are testing whether the once-weekly, high front-loaded dosing of rezafungin can result in improved patient outcomes versus the daily dosing of standard of care," chief medical officer Taylor Sandison said.Sandison also highlighted that the company is making "significant progress" in advancing the ReSTORE trial, with top-line data expected by the

For further details see:

Cidara Therapeutics posts new analyses from multiple rezafungin studies at ECCMID